201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.

Trial Profile

201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.

Completed
Phase of Trial: Phase III/IV

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Atazanavir; Elvitegravir; Non-nucleoside reverse transcriptase inhibitors; Nucleotide reverse transcriptase inhibitors; Peptide hydrolase inhibitors; Raltegravir
  • Indications HIV-1 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms STRIIVING
  • Sponsors GlaxoSmithKline; ViiV Healthcare
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Feb 2016 Results presented at the 23rd Conference on Retroviruses and Opportunistic Infections
    • 24 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top